The manufacture and characterization of protein nanoclusters
| dc.contributor.advisor | Johnston, Keith P., 1955- | |
| dc.contributor.advisor | Maynard, Jennifer Anne, 1974- | |
| dc.creator | Dinin, Aileen Kathryn | en |
| dc.date.accessioned | 2014-11-07T21:23:40Z | en |
| dc.date.accessioned | 2018-01-22T22:27:08Z | |
| dc.date.available | 2018-01-22T22:27:08Z | |
| dc.date.issued | 2013-05 | en |
| dc.date.submitted | May 2013 | en |
| dc.date.updated | 2014-11-07T21:23:41Z | en |
| dc.description | text | en |
| dc.description.abstract | The ability to formulate monoclonal antibodies at high concentration in a low-viscosity form is of broad interest in drug delivery, as monoclonal antibody-based drugs are now prescribed for cancer, autoimmune disorders, and many other diseases. Herein, we create highly concentrated antibody dispersions (up to 260 mg/mL) via three different methods, utilizing proline as an interacting depletant or trehalose as a non-interacting depletant. These dispersions are able to achieve viscosities an order of magnitude lower than similarly concentrated antibody solutions over a range of formulation pHs. When diluted, these antibody dispersions return to monomer. The proline acts to minimize protein zeta potential, thus reducing the electrostatic repulsion on the protein, even when formulated 3 pH units away from the antibody pI. In addition, it acts as a depletant, forcing the monomers into cluster via osmotic effects | en |
| dc.description.department | Chemical Engineering | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.uri | http://hdl.handle.net/2152/27207 | en |
| dc.subject | Protein | en |
| dc.subject | Monoclonal antibody | en |
| dc.subject | Formulation | en |
| dc.subject | Excipient | en |
| dc.subject | Viscosity | en |
| dc.subject | Equilibrium | en |
| dc.title | The manufacture and characterization of protein nanoclusters | en |
| dc.type | Thesis | en |